mazel / volgoat - you may be on to something. Perhaps you are correct and the first look-in has already taken place. But no announcement of same - yet. Here's an interesting scenario to contemplate - assuming the first look-in has indeed taken place - the results being in line or perhaps better than seen previously in the Phase II - but PPHM wants to make sure. So they wait for the second look-in sometime in the not too distant future. Assume the results stay consistent - or even show a slowly increasing survival curve.
With the above in mind - what would be the market reaction to a PR announcing the very favorable results of both look-ins, along with a DMC recommendation to unblind the trial and put all participants on the Bavi regimen?
An interesting scenario - and quite plausible. I'll be interested to hear your thoughts.
News 
Market Data 
Discover 
AI
